Genmab A/S Release: Teprotumumab Restarts Clinical Development in New Indication

Published: Jun 12, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; June 11, 2013 – Genmab A/S (OMX: GEN) announced today that teprotumumab (RG1507), an antibody developed by Genmab under our collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye disease. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche.

Help employers find you! Check out all the jobs and post your resume.

Back to news